Find clinical trials for Melanoma in Taipei City
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Melanoma trials near Taipei City, TWN:
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Taipei, Taiwan and 112 other locations
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...
Phase 2
Taipei, Taiwan and 43 other locations
assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...
Phase 3
Taipei, Taiwan and 130 other locations
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....
Phase 3
Taoyuan, Taiwan and 135 other locations
is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better ...
Phase 3
Taipei, Taiwan and 165 other locations
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Phase 1, Phase 2
Taipei City, Taiwan and 58 other locations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...
Phase 1
Taipei, Taiwan and 43 other locations
and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with N...
Phase 1
Taipei, Taiwan and 8 other locations
solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and nec...
Phase 2
Taipei, Taiwan and 9 other locations
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination w...
Phase 1
Taipei, Taiwan and 17 other locations
Clinical trials
Research sites
Resources
Legal